OSTX continues to develop marketing network
Ostex International Announces Expansion of Activities in Europe and South America; Executives Hired to Manage Sales and Marketing in UK and Latin America
Thursday, January 09, 1997 5:52 AM
SEATTLE--(BUSINESS WIRE)--Jan. 9, 1997--Ostex International, Inc. (NASDAQ: OSTX) announced today the appointments of John Wynne to Vice President, European Operations, and Victor L. Miranda, MD, MS, to Director, Latin American Sales. Ostex also announced it will create a European subsidiary based in Manchester, England.
John Wynne's responsibilities will include managing and supporting the company's existing distribution channels and building awareness of Osteomark in the European markets. Wynne brings over fifteen years experience working with companies in the biotechnology and medical device industries. Most recently, Wynne served as Vice President, Marketing and Business Development for IMR Corporation, a Seattle-based biotechnology company. From 1992 to 1996, Wynne created and managed IMR's first subsidiary located in Chester, UK. Prior to that, Wynne held a variety of positions in the UK subsidiaries of two multi-national healthcare companies, Fresenius Ltd. and Baxter International.
Victor Miranda will lead Ostex's sales efforts in Latin America, including expanding the existing distribution network and stimulating Latin America market demand. From June 1995 to December 1996, Miranda held the position of Interim Latin America Manager and Marketing Associate for LUNAR Corporation, a Madison, Wisconsin based company focused on developing products for the diagnosis, monitoring and treatment of osteoporosis and other metabolic bone diseases. Prior to joining LUNAR, Miranda was Executive Director of the Wisconsin Diagnostic and Rehabilitation Center in Madison, Wisconsin. Miranda holds a MD degree from the World University Medical School in Santo Domingo, Dominican Republic and a master in Rehabilitation Counseling from the University of Wisconsin.
Robert Glaser, President and Chief Operating Officer of Ostex commented, "The addition of these qualified individuals to our management team demonstrates our commitment to support our distributors and customers, and further develop the European and Latin American markets. The European market for biochemical markers is significant and growing at a rate equal or greater than the US market, and we recognize that each country has its own needs and characteristics. John's intimate knowledge of these markets will be invaluable to Ostex. In Latin America, anti-resorptive therapies are gaining acceptance and Victor's direct experience with our target markets positions Ostex to establish strong distribution channels for Osteomark at an early stage of this market's development."
Ostex International Inc. is engaged in the discovery, development, sales and marketing of diagnostics and therapeutics for diseases of the skeleton. The company believes its lead product, Osteomark, incorporates breakthrough technology in the area of bone resorption measurement. Ostex has formed collaborative relationships with a number of leading diagnostic and pharmaceutical companies to aid in the commercialization of Osteomark.
|
